Barclays Slashes Novo Nordisk's CagriSema Sales Forecast by 80%

Key Facts

Barclays analysts have significantly downgraded their peak sales expectations for Novo Nordisk's next-generation obesity drug, CagriSema. The forecast was slashed from $12 billion to just $2 billion, representing a massive 83% reduction in projected revenue. This drastic revision follows disappointing clinical trial results released a day earlier, which failed to meet high market expectations. The poor performance of CagriSema in recent trials raises concerns about its competitive positioning in the high-growth weight-loss market. Analysts noted that the downgrade reflects a more cautious outlook on the drug's long-term commercial viability and pipeline strength. Consequently, the news has weighed on investor sentiment regarding Novo Nordisk's future valuation and its ability to maintain market leadership.